Back to today’s briefing

Story perspectives

Allopurinol Becomes First Drug Approved for Marfan Syndrome

5/28/2025

35 8

Summary

Story summary

Allopurinol has made history as the first orphan drug designated for Marfan syndrome by the European Medicines Agency. This rare connective tissue disorder impacts 7 in 100,000 individuals in the EU, and the designation paves the way for crucial research. Exciting clinical trials are set to explore allopurinol's promise in preventing life-threatening aortic aneurysms.

1 of 1

Story summary

Allopurinol has made history as the first orphan drug designated for Marfan syndrome by the European Medicines Agency. This rare connective tissue disorder impacts 7 in 100,000 individuals in the EU, and the designation paves the way for crucial research. Exciting clinical trials are set to explore allopurinol's promise in preventing life-threatening aortic aneurysms.